Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: April 2012 (Announcement Date: April 20, 2012)
GSK announced an agreement to divest non-core over-the-counter (OTC) brands in international markets to Aspen Pharmacare Holdings Limited. This transaction is part of a broader strategy initiated in February 2011 to simplify the business and focus on priority brands.
Key Financial Metrics
- Transaction Value (International): £164 million in cash.
- Net Cash Proceeds (International): Approximately £135 million.
- Estimated Net Profit (International): £105 million pre-tax; £90 million post-tax (includes a £25 million pre-tax profit deferral due to Aspen being an associate).
- Divested Sales (International): Approximately £60 million in 2011.
- Total OTC Divestment Program (Global):
- Brands: USA, Canada, Europe, and International markets.
- Total 2011 Sales: Approximately £370 million.
- Total Gross Proceeds: £981 million.
- Total Net Proceeds: Approximately £690 million.
Material Changes and Transaction Details
The filing details the completion of a multi-region divestment strategy:
- International (Current): Agreement reached April 2012 with Aspen for brands including Phillips MOM, Solpadeine, Dequadin, Cartia, and Zantac. Completion expected in Q2 2012.
- USA & Canada (Completed): Agreement with Prestige Brands Holdings, Inc. for £426 million. The vast majority closed in January 2012, with proceeds returned via a supplemental dividend. The remainder closed in April 2012.
- Europe (Pending): Agreement with Omega Pharma for £391 million. Completion expected in Q2 2012.
Net cash proceeds from the international and European transactions are expected to be returned to shareholders during 2012.
Outlook, Risks, and Contingencies
- alli Divestment: GSK continues to plan to divest the weight-loss product alli. However, the process is delayed pending the resolution of a temporary third-party supply interruption.
- Regulatory Approvals: The completion of the international and European transactions is subject to regulatory approvals.
- Forward-Looking Statements: The filing includes a cautionary statement that actual results may differ materially from projections due to risks described in the company's 2011 Annual Report.
Investor Verification Checklist
- Verify the completion status of the international and European OTC divestments in Q2 2012.
- Confirm the resolution of the third-party supply interruption affecting the alli divestment.
- Monitor the timing and method of shareholder returns for the £135 million (international) and £310 million (Europe) net proceeds.
- Review the impact of the £25 million profit deferral on 2012 earnings due to the associate relationship with Aspen.